Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine
The use of volatile biomarkers in exhaled breath as predictors to individual drug response would advance the field of personalised medicine by providing direct information on enzyme activity. This would result in enormous benefits, both for patients and for the healthcare sector. Non-invasive breath...
Gespeichert in:
Veröffentlicht in: | Journal of breath research 2023-10, Vol.17 (4), p.46001 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 4 |
container_start_page | 46001 |
container_title | Journal of breath research |
container_volume | 17 |
creator | Lochmann, Franziska Nikolajevic, Aleksandar Stock, Valentina Kammerer, Sarah Fernández-Quintero, Monica L Loeffler, Johannes R Liedl, Klaus R Troppmair, Jakob Mayhew, Chris A Ruzsanyi, Veronika |
description | The use of volatile biomarkers in exhaled breath as predictors to individual drug response would advance the field of personalised medicine by providing direct information on enzyme activity. This would result in enormous benefits, both for patients and for the healthcare sector. Non-invasive breath tests would also gain a high acceptance by patients. Towards this goal, differences in metabolism resulting from extensive polymorphisms in a major group of drug-metabolizing enzymes, the cytochrome P450 (CYP) family, need to be determined and quantified. CYP2C9 is responsible for metabolising many crucial drugs (e.g., diclofenac) and food ingredients (e.g., limonene). In this paper, we provide a proof-of-concept study that illustrates the
bioconversion of diclofenac in recombinant HEK293T cells overexpressing CYP2C9 to 4'-hydroxydiclofenac. This
approach is a necessary and important first step in the development of breath tests to determine and monitor metabolic processes in the human body. By focusing on the metabolic conversion of diclofenac, we have been able to establish a workflow using a cell-based system for CYP2C9 activity. Furthermore, we illustrate how the bioconversion of diclofenac is limited in the presence of limonene, which is another CYP2C9 metabolising substrate. We show that increasing limonene levels continuously reduce the production of 4'-hydroxydiclofenac. Michaelis-Menten kinetics were performed for the diclofenac 4'-hydroxylation with and without limonene, giving a kinetic constant of the reaction,
, of 103
M and 94.1
M, respectively, and a maximum reaction rate,
, of 46.8 pmol min
10
cells
and 56.0 pmol min
10
cells
with and without the inhibitor, respectively, suggesting a non-competitive or mixed inhibition type. The half-maximal inhibitory concentration value (IC
) for the inhibition of the formation of 4'-hydroxydiclofenace by limonene is determined to be 1413
M. |
doi_str_mv | 10.1088/1752-7163/ace46f |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2839827280</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2839827280</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-8cac3640b1b2e618d7246543a9e4ded2f9388891a9b7eb982d978d16567385933</originalsourceid><addsrcrecordid>eNp1kc1O3DAUhS1UVGDaPStkqRsWpPgncezu0AjaSkjtAhZdRY593TEk8dROGPFAfU-cGTqVKtUbW9ffOb7XB6FTSj5SIuUlrStW1FTwS22gFO4AHe9Lb_bnqjpCJyk9ECJKItVbdMTrkgjB-DH6fZ1G3XY-rfzwE2tsoOuKViewOJkIMMzlTYiPrgsb7ELEFkaIvd9ejCvA4Jw3HgbzjIPDyx_f2VLhHrJryLb9J9yHpy0bNjratNVMCWa4jaDHFX4KnR59Bwn7Aa8hpjDoLM0t9GCz9wDv0KHTXYL3r_sC3d9c3y2_FLffPn9dXt0WhldqLKTRhucZW9oyEFTampWiKrlWUFqwzCkupVRUq7aGVklmVS0tFZWouawU5wt0vvNdx_BrgjQ2vU_zl-gBwpQaJjlXeeWvW6AP_6APYYq58S2VvWsmSabIjjIxpBTBNevoex2fG0qaOcJmzqiZ82p2EWbJ2avx1Ob594I_mWXgYgf4sP776H_9XgAeh6c9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2839827280</pqid></control><display><type>article</type><title>Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine</title><source>Institute of Physics Journals</source><creator>Lochmann, Franziska ; Nikolajevic, Aleksandar ; Stock, Valentina ; Kammerer, Sarah ; Fernández-Quintero, Monica L ; Loeffler, Johannes R ; Liedl, Klaus R ; Troppmair, Jakob ; Mayhew, Chris A ; Ruzsanyi, Veronika</creator><creatorcontrib>Lochmann, Franziska ; Nikolajevic, Aleksandar ; Stock, Valentina ; Kammerer, Sarah ; Fernández-Quintero, Monica L ; Loeffler, Johannes R ; Liedl, Klaus R ; Troppmair, Jakob ; Mayhew, Chris A ; Ruzsanyi, Veronika</creatorcontrib><description>The use of volatile biomarkers in exhaled breath as predictors to individual drug response would advance the field of personalised medicine by providing direct information on enzyme activity. This would result in enormous benefits, both for patients and for the healthcare sector. Non-invasive breath tests would also gain a high acceptance by patients. Towards this goal, differences in metabolism resulting from extensive polymorphisms in a major group of drug-metabolizing enzymes, the cytochrome P450 (CYP) family, need to be determined and quantified. CYP2C9 is responsible for metabolising many crucial drugs (e.g., diclofenac) and food ingredients (e.g., limonene). In this paper, we provide a proof-of-concept study that illustrates the
bioconversion of diclofenac in recombinant HEK293T cells overexpressing CYP2C9 to 4'-hydroxydiclofenac. This
approach is a necessary and important first step in the development of breath tests to determine and monitor metabolic processes in the human body. By focusing on the metabolic conversion of diclofenac, we have been able to establish a workflow using a cell-based system for CYP2C9 activity. Furthermore, we illustrate how the bioconversion of diclofenac is limited in the presence of limonene, which is another CYP2C9 metabolising substrate. We show that increasing limonene levels continuously reduce the production of 4'-hydroxydiclofenac. Michaelis-Menten kinetics were performed for the diclofenac 4'-hydroxylation with and without limonene, giving a kinetic constant of the reaction,
, of 103
M and 94.1
M, respectively, and a maximum reaction rate,
, of 46.8 pmol min
10
cells
and 56.0 pmol min
10
cells
with and without the inhibitor, respectively, suggesting a non-competitive or mixed inhibition type. The half-maximal inhibitory concentration value (IC
) for the inhibition of the formation of 4'-hydroxydiclofenace by limonene is determined to be 1413
M.</description><identifier>ISSN: 1752-7155</identifier><identifier>EISSN: 1752-7163</identifier><identifier>DOI: 10.1088/1752-7163/ace46f</identifier><identifier>PMID: 37406623</identifier><identifier>CODEN: JBROBW</identifier><language>eng</language><publisher>England: IOP Publishing</publisher><subject>4ʹ-hydroxydiclofenac ; bioconversion ; Breath tests ; CYP enzymes ; diclofenac ; HEK293T-CYP2C9 cells ; limonene ; Metabolism ; Nonsteroidal anti-inflammatory drugs ; Precision medicine</subject><ispartof>Journal of breath research, 2023-10, Vol.17 (4), p.46001</ispartof><rights>2023 The Author(s). Published by IOP Publishing Ltd</rights><rights>Creative Commons Attribution license.</rights><rights>2023 The Author(s). Published by IOP Publishing Ltd. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c359t-8cac3640b1b2e618d7246543a9e4ded2f9388891a9b7eb982d978d16567385933</cites><orcidid>0009-0009-6223-2329 ; 0000-0002-9284-2242 ; 0000-0002-5014-7241 ; 0000-0001-9631-364X ; 0000-0002-0985-2299 ; 0000-0002-6811-6283</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://iopscience.iop.org/article/10.1088/1752-7163/ace46f/pdf$$EPDF$$P50$$Giop$$Hfree_for_read</linktopdf><link.rule.ids>315,782,786,27933,27934,53855,53902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37406623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lochmann, Franziska</creatorcontrib><creatorcontrib>Nikolajevic, Aleksandar</creatorcontrib><creatorcontrib>Stock, Valentina</creatorcontrib><creatorcontrib>Kammerer, Sarah</creatorcontrib><creatorcontrib>Fernández-Quintero, Monica L</creatorcontrib><creatorcontrib>Loeffler, Johannes R</creatorcontrib><creatorcontrib>Liedl, Klaus R</creatorcontrib><creatorcontrib>Troppmair, Jakob</creatorcontrib><creatorcontrib>Mayhew, Chris A</creatorcontrib><creatorcontrib>Ruzsanyi, Veronika</creatorcontrib><title>Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine</title><title>Journal of breath research</title><addtitle>JBR</addtitle><addtitle>J. Breath Res</addtitle><description>The use of volatile biomarkers in exhaled breath as predictors to individual drug response would advance the field of personalised medicine by providing direct information on enzyme activity. This would result in enormous benefits, both for patients and for the healthcare sector. Non-invasive breath tests would also gain a high acceptance by patients. Towards this goal, differences in metabolism resulting from extensive polymorphisms in a major group of drug-metabolizing enzymes, the cytochrome P450 (CYP) family, need to be determined and quantified. CYP2C9 is responsible for metabolising many crucial drugs (e.g., diclofenac) and food ingredients (e.g., limonene). In this paper, we provide a proof-of-concept study that illustrates the
bioconversion of diclofenac in recombinant HEK293T cells overexpressing CYP2C9 to 4'-hydroxydiclofenac. This
approach is a necessary and important first step in the development of breath tests to determine and monitor metabolic processes in the human body. By focusing on the metabolic conversion of diclofenac, we have been able to establish a workflow using a cell-based system for CYP2C9 activity. Furthermore, we illustrate how the bioconversion of diclofenac is limited in the presence of limonene, which is another CYP2C9 metabolising substrate. We show that increasing limonene levels continuously reduce the production of 4'-hydroxydiclofenac. Michaelis-Menten kinetics were performed for the diclofenac 4'-hydroxylation with and without limonene, giving a kinetic constant of the reaction,
, of 103
M and 94.1
M, respectively, and a maximum reaction rate,
, of 46.8 pmol min
10
cells
and 56.0 pmol min
10
cells
with and without the inhibitor, respectively, suggesting a non-competitive or mixed inhibition type. The half-maximal inhibitory concentration value (IC
) for the inhibition of the formation of 4'-hydroxydiclofenace by limonene is determined to be 1413
M.</description><subject>4ʹ-hydroxydiclofenac</subject><subject>bioconversion</subject><subject>Breath tests</subject><subject>CYP enzymes</subject><subject>diclofenac</subject><subject>HEK293T-CYP2C9 cells</subject><subject>limonene</subject><subject>Metabolism</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Precision medicine</subject><issn>1752-7155</issn><issn>1752-7163</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>O3W</sourceid><recordid>eNp1kc1O3DAUhS1UVGDaPStkqRsWpPgncezu0AjaSkjtAhZdRY593TEk8dROGPFAfU-cGTqVKtUbW9ffOb7XB6FTSj5SIuUlrStW1FTwS22gFO4AHe9Lb_bnqjpCJyk9ECJKItVbdMTrkgjB-DH6fZ1G3XY-rfzwE2tsoOuKViewOJkIMMzlTYiPrgsb7ELEFkaIvd9ejCvA4Jw3HgbzjIPDyx_f2VLhHrJryLb9J9yHpy0bNjratNVMCWa4jaDHFX4KnR59Bwn7Aa8hpjDoLM0t9GCz9wDv0KHTXYL3r_sC3d9c3y2_FLffPn9dXt0WhldqLKTRhucZW9oyEFTampWiKrlWUFqwzCkupVRUq7aGVklmVS0tFZWouawU5wt0vvNdx_BrgjQ2vU_zl-gBwpQaJjlXeeWvW6AP_6APYYq58S2VvWsmSabIjjIxpBTBNevoex2fG0qaOcJmzqiZ82p2EWbJ2avx1Ob594I_mWXgYgf4sP776H_9XgAeh6c9</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Lochmann, Franziska</creator><creator>Nikolajevic, Aleksandar</creator><creator>Stock, Valentina</creator><creator>Kammerer, Sarah</creator><creator>Fernández-Quintero, Monica L</creator><creator>Loeffler, Johannes R</creator><creator>Liedl, Klaus R</creator><creator>Troppmair, Jakob</creator><creator>Mayhew, Chris A</creator><creator>Ruzsanyi, Veronika</creator><general>IOP Publishing</general><scope>O3W</scope><scope>TSCCA</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0009-6223-2329</orcidid><orcidid>https://orcid.org/0000-0002-9284-2242</orcidid><orcidid>https://orcid.org/0000-0002-5014-7241</orcidid><orcidid>https://orcid.org/0000-0001-9631-364X</orcidid><orcidid>https://orcid.org/0000-0002-0985-2299</orcidid><orcidid>https://orcid.org/0000-0002-6811-6283</orcidid></search><sort><creationdate>20231001</creationdate><title>Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine</title><author>Lochmann, Franziska ; Nikolajevic, Aleksandar ; Stock, Valentina ; Kammerer, Sarah ; Fernández-Quintero, Monica L ; Loeffler, Johannes R ; Liedl, Klaus R ; Troppmair, Jakob ; Mayhew, Chris A ; Ruzsanyi, Veronika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-8cac3640b1b2e618d7246543a9e4ded2f9388891a9b7eb982d978d16567385933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>4ʹ-hydroxydiclofenac</topic><topic>bioconversion</topic><topic>Breath tests</topic><topic>CYP enzymes</topic><topic>diclofenac</topic><topic>HEK293T-CYP2C9 cells</topic><topic>limonene</topic><topic>Metabolism</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Precision medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lochmann, Franziska</creatorcontrib><creatorcontrib>Nikolajevic, Aleksandar</creatorcontrib><creatorcontrib>Stock, Valentina</creatorcontrib><creatorcontrib>Kammerer, Sarah</creatorcontrib><creatorcontrib>Fernández-Quintero, Monica L</creatorcontrib><creatorcontrib>Loeffler, Johannes R</creatorcontrib><creatorcontrib>Liedl, Klaus R</creatorcontrib><creatorcontrib>Troppmair, Jakob</creatorcontrib><creatorcontrib>Mayhew, Chris A</creatorcontrib><creatorcontrib>Ruzsanyi, Veronika</creatorcontrib><collection>Institute of Physics Open Access Journal Titles</collection><collection>IOPscience (Open Access)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of breath research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lochmann, Franziska</au><au>Nikolajevic, Aleksandar</au><au>Stock, Valentina</au><au>Kammerer, Sarah</au><au>Fernández-Quintero, Monica L</au><au>Loeffler, Johannes R</au><au>Liedl, Klaus R</au><au>Troppmair, Jakob</au><au>Mayhew, Chris A</au><au>Ruzsanyi, Veronika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine</atitle><jtitle>Journal of breath research</jtitle><stitle>JBR</stitle><addtitle>J. Breath Res</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>17</volume><issue>4</issue><spage>46001</spage><pages>46001-</pages><issn>1752-7155</issn><eissn>1752-7163</eissn><coden>JBROBW</coden><abstract>The use of volatile biomarkers in exhaled breath as predictors to individual drug response would advance the field of personalised medicine by providing direct information on enzyme activity. This would result in enormous benefits, both for patients and for the healthcare sector. Non-invasive breath tests would also gain a high acceptance by patients. Towards this goal, differences in metabolism resulting from extensive polymorphisms in a major group of drug-metabolizing enzymes, the cytochrome P450 (CYP) family, need to be determined and quantified. CYP2C9 is responsible for metabolising many crucial drugs (e.g., diclofenac) and food ingredients (e.g., limonene). In this paper, we provide a proof-of-concept study that illustrates the
bioconversion of diclofenac in recombinant HEK293T cells overexpressing CYP2C9 to 4'-hydroxydiclofenac. This
approach is a necessary and important first step in the development of breath tests to determine and monitor metabolic processes in the human body. By focusing on the metabolic conversion of diclofenac, we have been able to establish a workflow using a cell-based system for CYP2C9 activity. Furthermore, we illustrate how the bioconversion of diclofenac is limited in the presence of limonene, which is another CYP2C9 metabolising substrate. We show that increasing limonene levels continuously reduce the production of 4'-hydroxydiclofenac. Michaelis-Menten kinetics were performed for the diclofenac 4'-hydroxylation with and without limonene, giving a kinetic constant of the reaction,
, of 103
M and 94.1
M, respectively, and a maximum reaction rate,
, of 46.8 pmol min
10
cells
and 56.0 pmol min
10
cells
with and without the inhibitor, respectively, suggesting a non-competitive or mixed inhibition type. The half-maximal inhibitory concentration value (IC
) for the inhibition of the formation of 4'-hydroxydiclofenace by limonene is determined to be 1413
M.</abstract><cop>England</cop><pub>IOP Publishing</pub><pmid>37406623</pmid><doi>10.1088/1752-7163/ace46f</doi><tpages>9</tpages><orcidid>https://orcid.org/0009-0009-6223-2329</orcidid><orcidid>https://orcid.org/0000-0002-9284-2242</orcidid><orcidid>https://orcid.org/0000-0002-5014-7241</orcidid><orcidid>https://orcid.org/0000-0001-9631-364X</orcidid><orcidid>https://orcid.org/0000-0002-0985-2299</orcidid><orcidid>https://orcid.org/0000-0002-6811-6283</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1752-7155 |
ispartof | Journal of breath research, 2023-10, Vol.17 (4), p.46001 |
issn | 1752-7155 1752-7163 |
language | eng |
recordid | cdi_proquest_journals_2839827280 |
source | Institute of Physics Journals |
subjects | 4ʹ-hydroxydiclofenac bioconversion Breath tests CYP enzymes diclofenac HEK293T-CYP2C9 cells limonene Metabolism Nonsteroidal anti-inflammatory drugs Precision medicine |
title | Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T11%3A31%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Establishing%20a%20cell-based%20screening%20workflow%20for%20determining%20the%20efficiency%20of%20CYP2C9%20metabolism:%20moving%20towards%20the%20use%20of%20breath%20volatiles%20in%20personalised%20medicine&rft.jtitle=Journal%20of%20breath%20research&rft.au=Lochmann,%20Franziska&rft.date=2023-10-01&rft.volume=17&rft.issue=4&rft.spage=46001&rft.pages=46001-&rft.issn=1752-7155&rft.eissn=1752-7163&rft.coden=JBROBW&rft_id=info:doi/10.1088/1752-7163/ace46f&rft_dat=%3Cproquest_pubme%3E2839827280%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2839827280&rft_id=info:pmid/37406623&rfr_iscdi=true |